{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:09:31Z","timestamp":1789027771338,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10552-026-02236-y","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:45:05Z","timestamp":1787643905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial and ethnic disparities in enrollment for clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in breast cancer treatment"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-1897","authenticated-orcid":false,"given":"Parnian","family":"Kheirkhah Rahimabad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Sekhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"1.0","key":"2236_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y et al (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15(1.0):121","journal-title":"J Hematol Oncol"},{"issue":"3.0","key":"2236_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"LHSR Cortesi","year":"2021","unstructured":"Cortesi LHSR, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 16(3.0):255\u2013282","journal-title":"Target Oncol"},{"issue":"1.0","key":"2236_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00411-3","volume":"8","author":"N Tung","year":"2022","unstructured":"Tung N, Garber JE (2022) PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer 8(1.0):47","journal-title":"NPJ Breast Cancer"},{"issue":"19.0","key":"2236_CR4","first-page":"3412","volume":"125","author":"LC Scott","year":"2010","unstructured":"Scott LC et al (2010) Update on triple-negative breast cancer disparities for the United States: a population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer 125(19.0):3412\u20133417","journal-title":"Cancer"},{"issue":"7.0","key":"2236_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jamaoncol.2021.1254","volume":"7","author":"B Cho","year":"2021","unstructured":"Cho B et al (2021) Evaluation of racial\/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol 7(7.0):1016\u20131023","journal-title":"JAMA Oncol"},{"key":"2236_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.576964","volume":"8","author":"O Prakash","year":"2020","unstructured":"Prakash O et al (2020) Racial disparities in triple negative breast cancer: a review of the role of biologic and non-biologic factors. Front Public Health 8:576964","journal-title":"Front Public Health"},{"issue":"4.0","key":"2236_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/0008-5472.CAN-20-3094","volume":"81","author":"F Wang","year":"2021","unstructured":"Wang F et al (2021) Racial\/ethnic disparities in all-cause mortality among patients diagnosed with triple-negative breast cancer. Cancer Res 81(4.0):1163\u20131170","journal-title":"Cancer Res"},{"issue":"21.0","key":"2236_CR8","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1182\/bloodadvances.2021005148","volume":"5","author":"A Hantel","year":"2021","unstructured":"Hantel A et al (2021) Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv 5(21.0):4352\u20134360","journal-title":"Blood Adv"},{"issue":"12","key":"2236_CR9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr et al (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol 33(12):1250\u20131268","journal-title":"Ann Oncol"},{"issue":"6","key":"2236_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533","journal-title":"N Engl J Med"},{"key":"2236_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2021.03.029","volume":"152","author":"KA Gelmon","year":"2021","unstructured":"Gelmon KA et al (2021) Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Eur J Cancer 152:68\u201377","journal-title":"Eur J Cancer"},{"issue":"11","key":"2236_CR12","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK et al (2020) Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31(11):1526\u20131535","journal-title":"Ann Oncol"},{"issue":"10","key":"2236_CR13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/oncolo\/oyad139","volume":"28","author":"JK Litton","year":"2023","unstructured":"Litton JK et al (2023) Neoadjuvant Talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study. Oncologist 28(10):845\u2013855","journal-title":"Oncologist"},{"issue":"8","key":"2236_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak S et al (2019) Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol 5(8):1132\u20131140","journal-title":"JAMA Oncol"},{"issue":"20","key":"2236_CR15","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/1078-0432.CCR-21-0310","volume":"27","author":"NC Turner","year":"2021","unstructured":"Turner NC et al (2021) Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG\/BIG5-13\/TESARO PR-30-50-10-C BRAVO study. Clin Cancer Res 27(20):5482\u20135491","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2236_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras V et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(10):1269\u20131282","journal-title":"Lancet Oncol"},{"issue":"2","key":"2236_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","volume":"24","author":"E Rodler","year":"2023","unstructured":"Rodler E et al (2023) Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 24(2):162\u2013174","journal-title":"Lancet Oncol"},{"issue":"1.0","key":"2236_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2022.01.032","volume":"165","author":"MK Wagar","year":"2022","unstructured":"Wagar MK et al (2022) Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers. Gynecol Oncol 165(1.0):49\u201352","journal-title":"Gynecol Oncol"},{"key":"2236_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221075458","volume":"14","author":"A Mazumder","year":"2022","unstructured":"Mazumder A et al (2022) The DNA damage repair landscape in Black women with breast cancer. Ther Adv Med Oncol 14:17588359221075458","journal-title":"Ther Adv Med Oncol"},{"key":"2236_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101807","author":"S Divekar","year":"2024","unstructured":"Divekar S et al (2024) Systemic DNA damage and repair activity vary by race in breast cancer survivors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16101807","journal-title":"Cancers (Basel)"},{"issue":"5.0","key":"2236_CR21","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-07-2206","volume":"7","author":"R Gao","year":"2008","unstructured":"Gao R et al (2008) Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther 7(5.0):1246\u20131250","journal-title":"Mol Cancer Ther"},{"issue":"13.0","key":"2236_CR22","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1158\/0008-5472.CAN-23-3458","volume":"84","author":"ML Cunningham","year":"2024","unstructured":"Cunningham ML, Schiewer MJ (2024) PARP-ish: gaps in molecular understanding and clinical trials targeting PARP exacerbate racial disparities in prostate cancer. Cancer Res 84(13.0):2049\u20132059","journal-title":"Cancer Res"},{"issue":"3.0","key":"2236_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12609-020-00364-1","volume":"12","author":"SSC Reid","year":"2020","unstructured":"Reid SSC, Pal T (2020) Disparities in genetic testing and care among Black women with hereditary breast cancer. Curr Breast Cancer Rep 12(3.0):125\u2013131","journal-title":"Curr Breast Cancer Rep"},{"issue":"1.0","key":"2236_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1748-0361.2012.00432.x","volume":"29","author":"D Sprague","year":"2013","unstructured":"Sprague D et al (2013) Barriers to cancer clinical trial participation among American Indian and Alaska Native tribal college students. J Rural Health 29(1.0):55\u201360","journal-title":"J Rural Health"},{"issue":"12.0","key":"2236_CR25","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/jnci\/djz091","volume":"111","author":"SL Gomez","year":"2019","unstructured":"Gomez SL, Yao S, Kushi LH, Kurian AW (2019) Is breast cancer in Asian and Asian American women a different disease? J Natl Cancer Inst 111(12.0):1243\u20131244","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2236_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.4143\/crt.2020.1381","volume":"53","author":"KH Lee","year":"2021","unstructured":"Lee KH, Sohn J, Goodwin A, Usari T, Lanzalone S, Im S-A, Kim S-B (2021) Talazoparib versus chemotherapy in patients with HER2-negative advanced breast cancer and a germline BRCA1\/2 mutation enrolled in Asian countries: exploratory subgroup analysis of the phase III EMBRACA trial. Cancer Res Treat 53(4):1084\u20131095","journal-title":"Cancer Res Treat"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-026-02236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-026-02236-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-026-02236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:48:57Z","timestamp":1789026537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-026-02236-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1007\/s10552-026-02236-y","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors have no conflicts of interest\/competing interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively from\u00a0publicly available data from the Surveillance, Epidemiology, and End Results Program (SEER) and previously published medical literature in accordance with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We used publicly available and de-identified data from the SEER and medical literature. No individual patient consent was needed.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"150"}}